Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Agios Pharmaceuticals, Inc. clinical trials
The registry lists 52 studies whose lead sponsor is Agios Pharmaceuticals, Inc.. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 13, 2026.
Keep track of what changes. Save the Agios Pharmaceuticals, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Agios Pharmaceuticals, Inc..
- Agios Pharmaceuticals, Inc.52 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 50 of 52. Browse all 52 →
- A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia VeraNot yet recruitingNCT07859423Phase 2/3
- A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat StudyEnrolling by invitationNCT05777993Phase 4
- A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)RecruitingNCT07656415Phase 3
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With PhenylketonuriaRecruitingNCT07241234Phase 1
- A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)RecruitingNCT07506863Phase 3
- A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent ThalassemiaRecruitingNCT07517133Phase 3
- A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)Active, not recruitingNCT05490446Phase 2
- Pyruvate Kinase Deficiency Global Longitudinal RegistryActive, not recruitingNCT03481738
- A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)Active, not recruitingNCT04770779Phase 3
- A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)Active, not recruitingNCT06924970Phase 2
- A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension PeriodActive, not recruitingNCT05144256Phase 3
- A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)Active, not recruitingNCT04770753Phase 3
- A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension PeriodActive, not recruitingNCT05175105Phase 3
- A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy ParticipantsActive, not recruitingNCT07075640Phase 1
- A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)Active, not recruitingNCT05031780Phase 2/3
- A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) DeficiencyCompletedNCT02476916Phase 2
- A Study of Mitapivat in Participants With Sickle Cell Disease and NephropathyWithdrawnNCT06286046Phase 2
- A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent ThalassemiaActive, not recruitingNCT03692052Phase 2
- Single and Multiple Ascending Dose Study and Food Effect Study for AG181CompletedNCT06286033Phase 1
- Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007CompletedNCT03853798Phase 3
- A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy ParticipantsCompletedNCT06745271Phase 1
- Study of How Mitapivat Affects Midazolam Blood Levels in Healthy ParticipantsCompletedNCT06648824Phase 1
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell DiseaseCompletedNCT04536792Phase 1
- Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008CompletedNCT04995315
- A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic FunctionCompletedNCT05610657Phase 1
- Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)TerminatedNCT04964323
- A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)CompletedNCT03548220Phase 3
- A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)CompletedNCT03559699Phase 3
- A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881CompletedNCT04128787Phase 1
- A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult ParticipantsCompletedNCT04696393Phase 1
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult ParticipantsCompletedNCT04472832Phase 1
- A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy ParticipantsCompletedNCT04565678Phase 1
- A Study of AG-636 in the Treatment of Subjects With Advanced LymphomaTerminatedNCT03834584Phase 1
- A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian ParticipantsCompletedNCT04145128Phase 1
- Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or LymphomaCompletedNCT03361358
- Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult ParticipantsCompletedNCT03991312Phase 1
- A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881CompletedNCT03960502Phase 1
- A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy AdultsCompletedNCT04015687Phase 1
- Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 MutationCompletedNCT02492737Phase 1
- A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348CompletedNCT03703505Phase 1
- Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 MutationApproved for marketingNCT03245424
- A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic FunctionCompletedNCT03282513Phase 1
- Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy AdultsCompletedNCT03397329Phase 1
- Japanese Bridging Study of Ivosidenib (AG-120) in Healthy SubjectsCompletedNCT03071770Phase 1
- Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian OriginCompletedNCT03250598Phase 1
- A Safety and Tolerability Study of AG-519 in Healthy SubjectsTerminatedNCT02630927Phase 1
- Drug-Drug Interaction Study of AG120 in Healthy SubjectsCompletedNCT02831972Phase 1
- Food Effect Study of AG120 in Healthy SubjectsCompletedNCT02579707Phase 1
- Food Effect Study of AG-221 in Healthy Male SubjectsCompletedNCT02218346Phase 1
- Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120CompletedNCT02489513Phase 1